Patents Assigned to Bausch & Lomb Pharma Holdings Corp.
  • Patent number: 10085958
    Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 2, 2018
    Assignee: BAUSCH & LOMB PHARMA HOLDINGS CORP.
    Inventors: Angel Padilla, George Baklayan
  • Publication number: 20170049735
    Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
    Type: Application
    Filed: November 4, 2016
    Publication date: February 23, 2017
    Applicant: BAUSCH & LOMB PHARMA HOLDINGS CORP.
    Inventors: Angel Padilla, George Baklayan
  • Patent number: 9517220
    Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: December 13, 2016
    Assignee: Bausch & Lomb Pharma Holdings Corp.
    Inventors: Angel Padilla, George Baklayan
  • Patent number: 8748402
    Abstract: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: June 10, 2014
    Assignee: Bausch & Lomb Pharma Holdings Corp.
    Inventors: Mark Abelson, Kirk McMullin, Angel Padilla